Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
OBJECTIVE
This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates.


METHODS
Population PK of LMV, STV and ZDV was separately evaluated from plasma concentrations obtained in 54, 39 and 27 HIV1-infected patients, respectively, enrolled in the COPHAR1-ANRS102 trial. The primary objective of this trial was to study the pharmacokinetics of indinavir (IDV) and nelfinavir (NFV) in treated patients with a sustained virological response. Concentrations of nucleoside analogs (NA) were measured in plasma as a secondary objective. A one-compartment model with first-order elimination was used, with zero-order absorption for LMV and first-order absorption for STV and ZDV.


RESULTS
Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively. For LMV, absorption duration (Ta) was 1.46 h (64%). For STV and ZDV, ka was 0.46 h(-1) and 2.9 h(-1), respectively. We found a systematic effect of combination with NFV vs. IDV. We found that intrapatient variability was greater than interpatient variability (except for STV) and greater than 55% for the three drugs.


CONCLUSIONS
This trial enabled the estimation of the population PK parameters of three NA in patients with a sustained virological response, and the median curves could be used as references for concentration-controlled strategies. We observed, as for the protease inhibitors, a great variability of PK parameters.
Panhard
Xavière
X
INSERM U738, 16 rue Henri Huchard, 75018, Paris, France. xaviere.panhard@bichat.inserm.fr
Legrand
Mayeule
M
Taburet
Anne-Marie
AM
Diquet
Bertrand
B
Goujard
Cécile
C
Mentré
France
F
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D023241:Antiretroviral Therapy, Highly Active; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019469:Indinavir / Q000494:pharmacology; D019259:Lamivudine / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D019888:Nelfinavir / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics*; D018119:Stavudine / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D015215:Zidovudine / Q000493:pharmacokinetics*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D018119:Stavudine; D019888:Nelfinavir
J Chromatogr B Biomed Sci Appl. 2000 Jul 21;744(2):227-40
10993510
Antimicrob Agents Chemother. 2000 Aug;44(8):2052-60
10898675
Antimicrob Agents Chemother. 1999 Dec;43(12):3025-9
10582904
Clin Pharmacokinet. 1996 Apr;30(4):314-27
8983861
Antimicrob Agents Chemother. 1998 Feb;42(2):409-13
9527795
Clin Pharmacol Ther. 1998 Sep;64(3):331-8
9757157
Antimicrob Agents Chemother. 1999 Jan;43(1):121-8
9869576
J Clin Pharmacol. 1999 Jun;39(6):593-605
10354963
Fundam Clin Pharmacol. 2005 Jun;19(3):373-83
15910662
Clin Pharmacokinet. 2005;44(12):1267-78
16372824
Antimicrob Agents Chemother. 2005 Aug;49(8):3361-6
16048948
Br J Clin Pharmacol. 2005 Oct;60(4):390-403
16187971
J Infect Dis. 1996 Jan;173(1):273
8537676
Antimicrob Agents Chemother. 1995 Oct;39(10):2309-15
8619587
Clin Pharmacokinet. 1995 Jul;29(1):46-65
7586898
Eur J Clin Pharmacol. 1993;45(5):397-407
8112367
Ann Intern Med. 1992 Apr 1;116(7):562-6
1347442
Biometrics. 1990 Sep;46(3):673-87
2242409
Clin Pharmacol Ther. 1990 Aug;48(2):161-7
2199132
Drugs. 2003;63(8):741-53
12662123
Fundam Clin Pharmacol. 2002 Oct;16(5):347-52
12602459
Antimicrob Agents Chemother. 2001 Jan;45(1):236-42
11120972
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
11768292
Soc Sci Med. 2002 May;54(10):1481-96
12061483